Neisseria gonorrhoeae (NG) is a common, global sexually transmitted infection that can have serious complications. There is increasing concern about the development of antimicrobial-resistant NG to extended-spectrum cephalosporins, which are the main drugs recommended for primary NG infection treatment globally [1–5]. Several countries have documented treatment failure to cephalosporins and/or elevated Minimum Inhibitory Concentrations (MICs) to ceftriaxone (MIC ≥0.25 μg/mL) [6–19] and widespread cephalosporin- resistant NG infection is anticipated to emerge, including emergence in Western Pacific and South-East Asia region countries [20]. The current research and development pipeline for new treatments of gonorrhea is very limited, with only three new antimicrobial products in various stages of clinical development [21].

As a result, surveillance is crucial for detecting and monitoring antimicrobial resistance (AMR). The WHO’s Gonococcal Antimicrobial Surveillance Programme (GASP), a global laboratory network, has monitored gonococcal antimicrobial susceptibility data since 1992; Thailand has been collecting these data since the inception of the program. There have been no isolates with reduced susceptibility to ceftriaxone or cefixime to date through GASP [22] or in other studies [23–27] in Thailand. However, two clinical isolates have recently been found to have elevated MICs to cephalosporins (e.g., cefixime and/or ceftriaxone) [28]. In addition to GASP, several other surveillance systems have been implemented in specific countries or regions to monitor trends for antimicrobial resistant NG. Each of these allow for the analysis of epidemiological and laboratory data including the Centers for Disease Control and Prevention’s (CDC) Gonococcal Isolate Surveillance Project (GISP) in the United States (U.S.) [29], Public Health England’s Gonococcal Resistance to Antimicrobials Surveillance Programme (UK-GRASP) in the United Kingdom [30], and the Australian Gonococcal Surveillance Programme (AGSP) [31].

The WHO GASP program collects susceptibility data from participating countries. Countries collect isolates through existing infrastructure and laboratory methods which vary across participating countries, making it difficult to compare susceptibility patterns across countries. GASP does not include demographic and behavioral data or information on unique individuals with NG infection, limiting its ability to identify populations at increased risk for antimicrobial-resistant NG. The Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) was implemented as a collaboration between the WHO and CDC to strengthen surveillance by standardizing data and laboratory collection for antimicrobial-resistant NG [32]. Selected surveillance sites in Bangkok, Thailand became the first setting to begin EGASP in November 2015. This manuscript describes the first year of EGASP surveillance in Thailand during November 2015 –October 2016 and are important for early detection of NG resistant strains and informing treatment options.

From November 2015 –October 2016, 3,143 men attended BH and 1,626 men attended SCC @TropMed. During this period, 1,026 (21.5%) men with urethritis visited one of the participating clinics and 1,102 specimens were collected as a part of EGASP Thailand. Most specimens (78.1%) were from BH. Among the 1,102 specimens, 582 (52.8%) were Gram stain positive for intracellular diplococci and 591 (53.6%) isolates were culture positive for NG infection; 511 (46.4%) specimens were neither Gram stain positive nor culture positive. After identification of NG infection, one isolate was found to be contaminated and was not further characterized (Table 1).

The majority of NG infections were treated according to the Thailand National Guidelines for Sexually Transmitted Diseases (STD) Treatment [4] with the recommended Ceftriaxone 250 mg IM (98.5% of cases) or Cefixime 400 mg PO (0.7% of cases); few cases (0.7%) received Azithromycin 2 gm PO only. In addition, the majority of cases (98.5%) were co-treated with another antibiotic for non-gonococcal urethritis: Azithromycin 1 gm PO (42.1% of cases), Azithromycin 2 gm PO (1.9% of cases), Doxycycline 100 mg PO (28.8% of cases), or another non-specified antibiotic (25.5% of cases).

The distribution of MIC values for the 590 NG isolates are presented for each antimicrobial in Fig 1. The majority of isolates (54.1%) had an MIC value of 0.004 μg/mL to ceftriaxone, 98.6% of isolates had an MIC value of ≤0.016 μg/mL to cefixime, and 32.4% of isolates had an MIC value of 0.064 μg/mL to azithromycin. Among isolates tested to gentamicin, 51.0% had an MIC value of 4.0 μg/mL and 42.7% had an MIC value of 8.0 μg/mL. No isolates had MICs at or above the final alert values for ceftriaxone, cefixime, azithromycin, or gentamicin. Overall, 545 (92.4%) isolates demonstrated resistance to ciprofloxacin with an MIC value ≥1.0 μg/mL.

More than half (65.1%) of the 1,026 men with urethritis had only female sex partners and 41.9% were 18–29 years (Table 2). Most men (97.6%) who went to the GMC clinic at BH had only female sex partners compared to the men that sought care at MHC at BH and SCC @TropMed who had only male sex partners (83.4% and 73.8%, respectively). The age distribution at each clinic was relatively the same; however, men aged 40 years and older primarily went to GMC at BH for services. Overall, 349 (34.0%) men with urethritis had recent antibiotic use in the previous 2 weeks before visiting a participating clinic; more men attending the GMC clinic at BH (39.2%) had recent antibiotic use than men attending other settings.

Of 1,026 men enrolled into EGASP, 564 (55.0%) unique men had NG infection and there were no identified treatment failures. However, among the 564 unique men with NG infection 23 men (4.1%) were diagnosed with a subsequent/repeat NG infection. Among 23 men with repeat NG infection, 20 (87.0%) had an infection diagnosed twice, 2 (8.7%) were diagnosed three times, and 1 (4.3%) was diagnosed more than four times. Men attending the SCC clinic @TropMed had more episodes with more than 1 NG infection (6.2%) compared to men attending a clinic at BH (3.6%). Among men with repeat NG infection, the median time between first and second NG diagnosis was 119 days (range 40–287 days), and the median between second and third NG diagnosis was 132 days (range 110–185 days).

These are the first data from EGASP, a surveillance system implemented by the Thailand MoPH, WHO and CDC to collect standardized data to monitor for global antimicrobial resistant NG infection. Similar to previously published estimates in the South-East Asia and Western Pacific Region, the vast majority of isolates (92%) in EGASP Thailand were resistant to ciprofloxacin. However, unlike other surveillance systems, all isolates were susceptible to cephalosporins and below an MIC of 2.0 μg/mL for azithromycin. Repeat NG infections occurred in 23 (4%) men; continued efforts to monitor repeat NG infection could support detection of persistent infections, NG treatment failures, and ultimately identify antimicrobial-resistant gonorrhea. Although no cephalosporin-resistant NG isolates were detected, this activity is timely given the emergence of cephalosporin resistance may occur first in South-East Asia [19, 20]. To monitor for emergent antimicrobial-resistant NG and detect early, continuation of EGASP Thailand, and expansion of EGASP to additional global settings, is critical.

Surveillance for antimicrobial-resistant NG with a focus on men with urethritis is appropriate given the need for an augmented global system that can be sustained through sentinel surveillance. MSM are at risk for STIs and in some settings, emergence of AMR occurred first in this population [38]. There was a high proportion of NG infection among MSM in EGASP Thailand, consistent with other studies in Thailand [39], as well as globally [38, 40–42].

There are a number of surveillance systems monitoring for antimicrobial resistant NG in other global settings, including WHO GASP [22], GISP in the U.S. [29], GRASP in the U.K. [30], and AGSP in Australia [31]; each of these surveillance systems have a number of strengths and limitations. The methods for NG identification and AST vary between the surveillance systems as well as the methods for collection of specimens and for monitoring QA/QC processes. Most systems, except WHO GASP, collect some demographic and behavioral data; however, the variables collected across systems are not the same. One challenge with assessing and tracking global antimicrobial resistant NG is the lack of standardized methods across different settings. While WHO GASP is a well-established global surveillance system and is feasible in many settings, it does not collect information on unique individuals, have standardized laboratory methods (e.g., not all settings provide data on MIC values or detect AMR in the same way), or collect demographic, behavioral or clinical information. Core epidemiologic data could be used to support development of effective interventions to prevent the spread of AMR in global settings. EGASP was established to address the limitations of global systems by including standardized demographic, behavioral, clinical and laboratory data, and augmenting surveillance with quality assurance and control measures.

Despite differences in methods for NG surveillance systems globally, it is important to compare EGASP MIC results to those from other systems. The absence of any isolates with final alerts to ceftriaxone, cefixime and azithromycin is lower than published data from other surveillance systems [29–31], however using an MIC of 0.03 μg/mL as a threshold of reduced susceptibility to ceftriaxone according to previous studies [43–46], 2% of NG isolates met this threshold. Overall, 545 (92.4%) isolates demonstrated resistance to ciprofloxacin with an MIC value ≥1.0 μg/mL. This is similar to reports from other countries in the Southeast Asia and Western Pacific regions but is higher than other parts of the world [22, 29]. This distribution of gentamicin MICs is similar to that of previously published reports from other surveillance systems [47]

There was strict attention to the quality of clinical and laboratory data in EGASP Thailand. Although the BH and SCC @TropMed surveillance sites differed in methods of data collection (i.e., paper versus electronic medical charts), the core variables collected between the two surveillance sites were the same and sites could expand on this collection, if desired. Methods for specimen collection, including Gram’s stain, NG culture, identification, and AST were standardized across both surveillance sites. Quality control steps, such as a training and a biannual external quality assessment, were implemented to ensure laboratory quality. Additionally, EGASP Thailand conducted an internal quality assessment (IQA) evaluation in September 2016 to assess data quality [48]. Data from the original source documents (i.e., the medical records and laboratory record books), were compared to the electronic EGASP database as well as the EGASP abstraction form. Clinic staff from each surveillance site conducted the IQA review of the other setting with 10% of cases randomly selected for review. The IQA allowed surveillance personnel to implement improvement measures, including the use of standardized reporting forms, improved systems to prevent data entry errors, and a refresher training to all staff involved in EGASP. The standardization of methods, laboratory activities and assessments, as well as the internal evaluation, were important to increase the reliability of the surveillance data collected.

One unique attribute of EGASP Thailand was the ability to track and evaluate individual men with NG infection and identify those who had repeat infections. Repeat infections are likely re-infections, but they also could be a sentinel event indicating a persistent infection and possible treatment failure, which could suggest antimicrobial-resistant NG infection. Both tests for cure, and evaluation of repeat infections, might support early detection of treatment failure and support a response plan that includes contact tracing and other public health control steps. Many low- and middle-income settings have limited partner notification systems, but a focused effort on potential treatment failures may be feasible. Because most antimicrobial-resistant NG surveillance is based on specimens alone, the opportunity to find early treatment failure is limited to those that have evidence of in vitro resistance. Taking steps to have unique patient identifiers connected to NG isolates in a surveillance system is important to assess attributes of persons with antimicrobial-resistant NG, evaluate for clearance of infection, and implement control steps early in the case of treatment failure.

There are a number of limitations of EGASP. We evaluated only men with urethritis with a urethral specimen, in two clinical settings in Bangkok, Thailand; these data may not be generalizable. However, the collection of data in symptomatic men was purposeful as this population provides a high yield for culture. Depending on the global setting, inclusion of other clinical settings, populations at risk, and anatomic sites, are important to consider. While culture capacity is critical to provide susceptibility data, culture has lower sensitivity than nucleic acid amplification testing; therefore, the number of men with gonorrhea in our surveillance system may have been underestimated. Additionally, the inclusion of specimens from the oropharynx and rectum could be beneficial; especially as some studies have detected that AMR might occur more frequently in the oropharynx [9, 13, 49–53]. Lastly, we collected limited demographic, behavioral, and co-infection information; surveillance sites might be able to consider augmenting the core variables, depending on their setting, to include additional risk information for their populations.

In summary, EGASP was established by WHO and CDC to collect standardized and systematic data to monitor trends of antimicrobial-resistant NG. Recent reports on cases of antimicrobial resistant NG infection highlight the importance of this surveillance globally [19]. Data collected from the first EGASP site in Thailand will be used to inform future treatment guidelines in Thailand and the region. The expansion of EGASP to different global settings would augment the ability to detect antimicrobial resistant NG and initiate timely prevention and control steps globally.